Swedish Orphan Biovitrum (BIOVF) Projected to Post Earnings on Tuesday

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) is anticipated to announce its results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of $0.62 per share and revenue of $890.88 million for the quarter.

Swedish Orphan Biovitrum Stock Down 0.6%

Shares of OTCMKTS:BIOVF opened at $45.72 on Friday. The firm has a market capitalization of $16.27 billion, a PE ratio of 101.59 and a beta of 0.47. The business has a 50 day simple moving average of $46.31 and a two-hundred day simple moving average of $46.45. Swedish Orphan Biovitrum has a 1 year low of $34.88 and a 1 year high of $49.03. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55.

Analyst Upgrades and Downgrades

BIOVF has been the subject of a number of research reports. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st. Nordea Equity Research cut shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.